Joshua M. Lang, MD, on Prostate Cancer: Best of the Journals

2017 Genitourinary Cancers Symposium
Tweet this page

Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.

Advertisement

Advertisement



Advertisement

click me